Multiple Myeloma: all 3,712 studies
Page 25 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life ConditionsCompletedNCT03353545
- Daratumumab After Stem Cell Transplant in Treating Patients With Multiple MyelomaActive, not recruitingNCT03346135Phase 2
- Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.CompletedNCT03344328
- Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple MyelomaStatus unknownNCT03336073Phase 2
- Study of Personalized Melphalan Dosing in the Setting of Autologous TransplantWithdrawnNCT03328936Phase 2
- Use of Zarzio® in Post-autologous Stem Cell Transplantation ProcedureCompletedNCT03323541
- Study of BCMA CAR-T in Multiple MyelomaStatus unknownNCT03322735Phase 1/2
- A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantActive, not recruitingNCT03319667Phase 3
- Identification of Occupational Exposures in Acute Hematologic MalignancyCompletedNCT03316209
- Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisActive, not recruitingNCT03315026Phase 2
- A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03314181Phase 2
- CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid MalignanciesStatus unknownNCT03312205Phase 1/2
- Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaCompletedNCT03311828Phase 1
- Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple MyelomaCompletedNCT03309111Phase 1
- ASCT With Nivolumab in Patients With Multiple MyelomaActive, not recruitingNCT03292263Phase 1/2
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in KoreaCompletedNCT03288974
- A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03288480Phase 1
- A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03287908Phase 1
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell TransplantationCompletedNCT03276481
- Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)CompletedNCT03275103Phase 1
- Study of bb21217 in Multiple MyelomaCompletedNCT03274219Phase 1
- Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03266692Phase 1
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03242889Phase 1
- The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)CompletedNCT03242460Phase 2
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Phase 3
- High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal ImpairmentCompletedNCT03234335
- Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCTCompletedNCT03233776Phase 2
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
- Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.Active, not recruitingNCT03225417Phase 1/2
- Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Phase 3
- A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without PomalidomideCompletedNCT03215524Phase 2
- Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple MyelomaStatus unknownNCT03210753
- Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03200626
- Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRPTerminatedNCT03196947Phase 1/2
- Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2
- Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT03190525
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- Nivolumab Combined With Daratumumab With or Without Low-dose CyclophosphamideCompletedNCT03184194Phase 2
- Multiple Myeloma Patient RegistryTerminatedNCT03180853
- Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple MyelomaTerminatedNCT03173430Early Phase 1
- A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)TerminatedNCT03173092Phase 4
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
- Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment LinesCompletedNCT03155100Phase 2
- CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple MyelomaStatus unknownNCT03150316Phase 1
- Diagnostic Imaging of Myeloma Bone LesionsCompletedNCT03147326Not applicable
- Prevalence of Asymptomatic Thrombosis in Multiple MyelomaWithdrawnNCT03145870Not applicable
- Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT03143985Phase 1
- Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory MyelomaStatus unknownNCT03143049Phase 3
- Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory MyelomaStatus unknownNCT03143036Phase 2
- Decision Aid Website in Helping to Make Decisions About Fertility in Participants With CancerActive, not recruitingNCT03141437Not applicable
- Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT03140943Phase 2
- A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaCompletedNCT03136653Phase 1/2
- Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell TransplantationCompletedNCT03135925Not applicable
- Expanded Access to Elotuzumab (Empliciti) for Multiple MyelomaNo longer availableNCT03126617
- cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study.Status unknownNCT03122327
- Dysregulation of Glutamine Activity in the Pathogenesis of Multiple MyelomaCompletedNCT03119883Not applicable
- Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)CompletedNCT03119363Not applicable
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedNCT03111992Phase 1
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1
- A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for TransplantCompletedNCT03106324
- Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and DexamethasoneActive, not recruitingNCT03104842Phase 2
- Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
- Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple MyelomaWithdrawnNCT03100877Phase 1/2
- BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple MyelomaStatus unknownNCT03093168Phase 1
- Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)Status unknownNCT03091933Phase 1/2
- A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT03091257Phase 1
- Real-world Use of Carfilzomib Among Multiple Myeloma Patients in EuropeCompletedNCT03091127
- LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple MyelomaActive, not recruitingNCT03090659Phase 1/2
- Collection of Additional Data Followed the Study IFM 2013-04Status unknownNCT03089411
- BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple MyelomaCompletedNCT03070327Phase 1
- Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple MyelomaCompletedNCT03068637Not applicable
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaCompletedNCT03068351Phase 1
- Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid TumorsTerminatedNCT03061305
- CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple MyelomaStatus unknownNCT03051841Phase 1
- Improving the Quality of Multiple Myeloma Treatment With Patient Care PlansCompletedNCT03046329Not applicable
- Vaccination With PD-L1 Peptide Against Multiple MyelomaCompletedNCT03042793Phase 1
- A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple MyelomaTerminatedNCT03033316Phase 1/2
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedNCT03023527Phase 1
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLCompletedNCT03019666Phase 1
- A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsStatus unknownNCT03018405Phase 1/2
- Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaStatus unknownNCT03015922Phase 1
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
- Mobile Health Device Study for Myeloma PatientsCompletedNCT03006315
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnNCT03003728Phase 2
- Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible PatientsCompletedNCT03001804
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWithdrawnNCT03000634Phase 2
- A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple MyelomaTerminatedNCT02998047Phase 1
- Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization StrategiesCompletedNCT02997813
- Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
- Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory MyelomaWithdrawnNCT02986451Phase 2
- Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple MyelomaWithdrawnNCT02985333Phase 2
- Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma PatientsStatus unknownNCT02981199Not applicable
- A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaTerminatedNCT02978235Phase 1
- Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal ImpairmentCompletedNCT02977494Phase 2
- Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple MyelomaCompletedNCT02976493